June 24, 2026

Rise in Colorectal Cancer Among Young Adults in Germany as Well – But below US Levels

Rise in Colorectal Cancer Among Young Adults in Germany as Well – But below US Levels

Colorectal cancer is generally considered a disease of older adults. However, a new analysis of German cancer registries shows that the number of new colorectal cancer cases among younger adults has risen slightly over the past two decades. Those most affected are people between the ages of 20 and 39. The findings are based on data from ten German cancer registries and cover the period from 2003 to 2023.

“Early-onset” colorectal cancer (EOCRC) refers to cases diagnosed before the age of 50. However, reports of rising colorectal cancer rates among younger people—particularly from the U.S.—prompted scientists at the German state cancer registries to take a closer look at the disease situation in Germany

Marked Increase Among the Youngest

For the current analysis, the experts evaluated more than 28,000 cases of colorectal cancer in people aged 20 to 49. They found that the incidence of colorectal cancer increased among 20- to 29-year-olds as well as among 30- to 39-year-olds. The increase was particularly pronounced in the youngest age group. Among 40- to 49-year-olds, however, the incidence rate remained largely stable overall.

“Our results show that the rise in colorectal cancer among young adults in Germany is real, but—at least so far—it is significantly more moderate than in the U.S.,” says Volker Arndt of the German Cancer Research Center (DKFZ) and the Baden-Württemberg Cancer Registry, one of the study’s two senior authors.

Germany Well Below U.S. Levels

An important part of the study was the comparison with the United States, where the rise in colorectal cancer among younger adults has been the subject of intense debate for years. The researchers show that incidence rates in Germany are significantly lower than in the U.S., both at the beginning of the study period and currently. Furthermore, the increase has been much slower in Germany.

Why Are the Numbers Rising?

The causes have not yet been fully explained. Lifestyle changes, including obesity, lack of physical activity, and dietary habits, are being discussed as possible contributing factors. Changes in gut flora could also play a role.

At the same time, the results suggest that part of the observed increase could be attributed to earlier and improved diagnosis. In particular, there was an increase in tumors with a comparatively favorable prognosis, which are often detected at an early stage.

No Reason to Lower the Screening Age Across the Board

Despite this trend, the authors currently see no sufficient reason to lower the age limit for colorectal cancer screening in the general population to under 50 years. “Colorectal cancer before the age of 50 remains rare overall in Germany,” emphasizes Jacqueline Müller-Nordhorn of the Bavarian Cancer Registry at the Bavarian State Office for Health and Food Safety. “Of the approximately 56,000 new cases of colorectal cancer each year, only about five percent occur in people under 50. Nevertheless, it should be noted that younger people should, of course, seek prompt, individualized medical care if they experience symptoms. The priority is to consistently identify known risk groups—such as people with a family history of the disease—and offer them the recommended screening tests.

The researchers recommend continuing to closely monitor trends in the incidence of the disease. Future studies should focus on clarifying the role that early life lifestyle factors, obesity, the consumption of highly processed foods, antibiotic use, and/or changes in the gut microbiota play in the development of colorectal cancer at a young age.

Sven Voigtländer, Hiltraud Kajüter, Ina Wellmann, Andras Szentkirályi, Bernd Holleczek, Volker Arndt, Jacqueline Müller-Nordhorn, and the ALSTER Working Group: Incidence trends of early-onset colorectal cancer in Germany: A registry-based study from 2003 to 2023
International Journal of Cancer, 2026, DOI: 10.1002/ijc.70600

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp